Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN3B | O60391 | 4/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850156 | 0.80 | USP7 (0.40) | GRIN3BGRIN1GRIN2C | |
| SCHEMBL26916027 | 0.78 | GRIN3B (0.45) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL29997769 | 0.78 | KDM4E (0.32) | RAB9A | |
| SCHEMBL23666994 | 0.78 | KDM4E (0.32) | RAB9A | |
| SCHEMBL13166681 | 0.77 | MET (0.36) | GRIN3BGRIN1GRIN2C | |
| SCHEMBL23911563 | 0.77 | MAPKAPK2 (0.34) | NPC1RAB9A | |
| SCHEMBL26916157 | 0.77 | GRIN3B (0.39) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL25282439 | 0.76 | LOXL2 (0.38) | — | |
| SCHEMBL25739758 | 0.76 | USP7 (0.31) | — | |
| SCHEMBL23911307 | 0.76 | LMNA (0.44) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | GRIN3B 3585/4885GRIN1 3686/4885GRIN2C 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.